Sorafenib versus Transarterial chemoembolization for advanced-stage hepatocellular carcinoma: a cost-effectiveness analysis

Table 3 Base Case Value and Range of Utilities Extracted from Literatures

Variables	Base case value	Range
Compensated cirrhosis without progressive HCC⁵²	0.76	0.76–0.80
Compensated cirrhosis with progressive HCC⁵²	0.68	0.60–0.68
Decompensated cirrhosis⁵³	0.57	0.46–0.68

ISSN: 1471-2407